ABSTRACT. Whole brain radiotherapy (WBRT) is the standard non-surgical treatment for brain metastatic disease, but rarely eradicates bulky metastases from most common cancers. Recent literature has demonstrated the safety and efficacy of delivering very high focal doses of radiation (by radiosurgical techniques) to the gross tumour volume of bulky brain metastases, thereby obtaining more certain local control than is achieved by WBRT. In this paper we report a study of 11 patients with bulky brain metastases in whom an intensity-modulated radiation therapy (IMRT) facility has been used to concomitantly boost the gross tumour volume of bulky brain metastatic disease (to 40 Gy) during a standard 30 Gy in 10 fractions WBRT schedule. No acute or subacute morbidity was encountered, and good early control data were noted. We discuss the perceived advantages of such a technique. Many patients who develop brain metastases will eventually die of progressive intracranial disease. Among selected patients with good performance status, controlled extracranial disease, favourable prognostic features and with a solitary brain metastasis, there are data from randomised clinical studies demonstrating that surgical excision followed by whole brain radiotherapy (WBRT) offers prolonged survival [5,6]. Stereotactic radiosurgery (SRS), using technologies such as Gamma Knife (Elekta, Linkoping, Sweden), may be able to replace surgery in certain circumstancesdelivering obliteratively high single doses to discrete (single) metastases. SRS is well suited to treating small numbers of brain metastases and achieves good local control of intracranial metastases [7,8]. The doses that can be delivered to individual metastases by Gamma Knife SRS (up to 25 Gy on the margin of MRI-mapped lesions) offer a greater degree of certainty of local control than those from routine WBRT dose prescription. The Radiation Therapy Oncology Group (RTOG) 9508 trial randomised 333 patients with one to three cerebral metastases to standard WBRT either with or without a stereotactic radiation boost and demonstrated an improved quality and quantity of life in those receiving the stereotactic boost [9]. This level 1 evidence thereby demonstrated that packing a higher radiation dose into bulky cerebral metastases is beneficial in addition to standard WBRT.Many patients are initially deemed unsuitable for neurosurgery or, later, SRS boost, owing to poor performance status, active extracranial disease or multiple brain metastases. In these patients, corticosteroids and WBRT are standard treatment. However, there is a subset of these patients receiving WBRT who have better prognostic factors from the systemic disease viewpoint, and who survive long enough to later die from uncontrolled brain metastatic disease. Benefit from brain radiation therapy was greater for the recursive partitioning analysis (RPA) Class I patients (age ,65 years, Karnofsky performance status 70% or higher, with a controlled primary tumour and no extracranial metastases) in the RTOG database [10]. ...